Published in Can J Cardiol on May 01, 2009
2010 Canadian Hypertension Education Program recommendations: An annual update. Can Fam Physician (2010) 1.45
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
Canadian efforts to prevent and control hypertension. Can J Cardiol (2010) 1.11
Underrepresentation of individuals 80 years of age and older in chronic disease clinical practice guidelines. Can Fam Physician (2011) 1.09
Annual adult health checkup: update on the Preventive Care Checklist Form(©). Can Fam Physician (2012) 1.08
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2010) 1.07
Lifestyle medicine for depression. BMC Psychiatry (2014) 1.03
A review of nutritional factors in hypertension management. Int J Hypertens (2013) 1.01
2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol (2010) 0.99
Management of hypertension and diabetes in obesity: non-pharmacological measures. Int J Hypertens (2011) 0.94
Association between physical activity and cardiovascular risk in Chinese youth independent of age and pubertal stage. BMC Public Health (2010) 0.92
Renal tissue oxygenation in essential hypertension and chronic kidney disease. Int J Hypertens (2013) 0.86
General practitioners' hypertension knowledge and training needs: a survey in Xuhui district, Shanghai. BMC Fam Pract (2013) 0.84
Access to health care and heavy drinking in patients with diabetes or hypertension: implications for alcohol interventions. Subst Use Misuse (2012) 0.83
Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol (2012) 0.82
Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol (2011) 0.80
Addressing poor nutrition to promote heart health: moving upstream. Can J Cardiol (2010) 0.80
Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature. J Cell Mol Med (2010) 0.79
Hypertension and type 2 diabetes: what family physicians can do to improve control of blood pressure--an observational study. BMC Fam Pract (2011) 0.79
Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension. Can J Cardiol (2010) 0.79
The current status of beta blockers' use in the management of hypertension. Saudi Med J (2014) 0.79
Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. Br J Clin Pharmacol (2011) 0.79
Appreciating the medical literature: five notable articles in general internal medicine from 2009 and 2010. Open Med (2011) 0.78
Management of hypertension: Regional variations in a greatly improved landscape. Can J Cardiol (2010) 0.77
Collaborative Cardiovascular Risk Reduction in Primary Care II (CCARP II): Implementation of a systematic case-finding process for patients with uncontrolled risk factors. Can Pharm J (Ott) (2013) 0.77
Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis. CMAJ Open (2017) 0.75
Communication and patient participation influencing patient recall of treatment discussions. Health Expect (2016) 0.75
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 17.97
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med (2004) 11.47
Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis (1998) 10.70
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA (2001) 8.15
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol (1998) 6.76
Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med (2007) 5.82
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet (1999) 3.81
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens (2005) 3.27
Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ (1992) 2.98
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol (2003) 2.52
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
Blood pressure and survival in the oldest old. J Am Geriatr Soc (2007) 1.98
The Canadian Hypertension Education Program--a unique Canadian initiative. Can J Cardiol (2006) 1.76
Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation (2000) 1.74
Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol (2006) 1.74
The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. Can J Cardiol (2004) 1.73
Risk of hypertension amongst Swedish male snuff users: a prospective study. J Intern Med (2008) 1.69
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Can J Cardiol (2004) 1.46
Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol (2005) 1.44
The 2000 Canadian recommendations for the management of hypertension: Part one--therapy. Can J Cardiol (2001) 1.42
Smoking and the risk of incident hypertension in middle-aged and older men. Am J Hypertens (2008) 1.35
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens (2008) 1.29
The COOPERATE trial: a letter of concern. Lancet (2008) 1.03
Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther (2008) 0.90
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown) (2006) 0.85
Differences in need for antihypertensive drugs among those aware and unaware of their hypertensive status: a cross sectional survey. BMC Cardiovasc Disord (2005) 0.84
Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. Hypertension (2008) 0.82
Making hypertensive smokers motivated in quitting: developing 'blood pressure equivalence of smoking'. J Hypertens (2008) 0.77
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78
Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med (2015) 12.70
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet (2007) 8.68
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med (2004) 8.07
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 5.32
Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA (2004) 4.82
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol (2013) 4.75
Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med (2013) 4.49
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care (2008) 4.20
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke (2005) 4.07
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ (2007) 3.99
N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation (2007) 3.97
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ (2003) 3.85
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol (2007) 3.72
Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med (2007) 3.71
When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int (2009) 3.70
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Long-term analgesic use after low-risk surgery: a retrospective cohort study. Arch Intern Med (2012) 3.52
Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA (2012) 3.46
Hypertriglyceridemia: its etiology, effects and treatment. CMAJ (2007) 3.42
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med (2012) 3.38
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr (2008) 3.33
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26
GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension (2011) 3.26
Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA (2008) 3.25
Body mass index and mortality in heart failure: a meta-analysis. Am Heart J (2008) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Endothelial dysfunction. J Am Soc Nephrol (2004) 3.18
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med (2011) 3.13
NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care (2008) 3.07
Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med (2008) 3.06
Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med (2007) 3.06
Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol (2012) 3.03
Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA (2003) 3.03
Anesthetic management and outcome in patients during endovascular therapy for acute stroke. Anesthesiology (2012) 3.02
Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med (2009) 2.96
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol (2012) 2.94
Methodology of the Interventional Management of Stroke III Trial. Int J Stroke (2008) 2.88
Results of the Ontario survey on the prevalence and control of hypertension. CMAJ (2008) 2.88
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
The frequency and characteristics of dietary supplement recalls in the United States. JAMA Intern Med (2013) 2.81
Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke (2010) 2.79
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke (2006) 2.77
Validation of a case definition to define hypertension using administrative data. Hypertension (2009) 2.74
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med (2009) 2.63
Job strain and risk of acute recurrent coronary heart disease events. JAMA (2007) 2.61
Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA (2010) 2.61
Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med (2012) 2.58
Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. Kidney Int (2008) 2.56
Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med (2012) 2.54
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension (2009) 2.47
Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors. Kidney Int (2013) 2.42
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ (2011) 2.40
Redox signaling in hypertension. Cardiovasc Res (2006) 2.37
Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke (2007) 2.36
Narrative review: statin-related myopathy. Ann Intern Med (2009) 2.36
Prolonged antibiotic treatment in long-term care: role of the prescriber. JAMA Intern Med (2013) 2.35
A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35
Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol (2013) 2.34
Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ (2011) 2.34
Demographics and concomitant disorders in heart failure. Lancet (2003) 2.30